The DOI matches its Crossref record; 393 of the 393 references it cites were found in a registry or an index.
Molecular Targets for Antiepileptic Drug Development
Open accessOverview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Shrestha, S., & Offer, S. M. (2016) · Medical Epigenetics · doi:10.1159/000444713 · Cited by 8,914
Glutamate neurotoxicity and diseases of the nervous system
CHOI, D. (1988) · Neuron · doi:10.1016/0896-6273(88)90162-6 · Cited by 7,972
International Union of Pharmacology: Approaches to the Nomenclature of Voltage-Gated Ion Channels
Catterall, W. A., Chandy, K. G., Clapham, D. E., Gutman, G. A., Hofmann, F., Harmar, A. J., Abernethy, D. R., & Spedding, M. (2003) · Pharmacological Reviews · doi:10.1124/pr.55.4.5 · Cited by 7,126
Early Identification of Refractory Epilepsy
Kwan, P., & Brodie, M. J. (2000) · New England Journal of Medicine · doi:10.1056/nejm200002033420503 · Cited by 5,204
Danbolt, N. C. (2001) · Progress in Neurobiology · doi:10.1016/s0301-0082(00)00067-8 · Cited by 4,227
Glutamate receptor ion channels
Mayer, M. L. (2005) · Current Opinion in Neurobiology · doi:10.1016/j.conb.2005.05.004 · Cited by 3,640
The Glutamate Receptor Ion Channels
Dingledine, R., Borges, K., Bowie, D., & Traynelis, S. F. (1999) · Pharmacological Reviews · doi:10.1016/s0031-6997(24)01394-2 · Cited by 3,554 · cited 1×
“All NMDA receptors contain an NR1 subunit, which exists as eight splice variants.(221) TABLE 6.”
Pierce, K. L., Premont, R. T., & Lefkowitz, R. J. (2002) · Nature Reviews Molecular Cell Biology · doi:10.1038/nrm908 · Cited by 2,701
Catterall, W. A., Goldin, A. L., & Waxman, S. G. (2005) · Pharmacological Reviews · doi:10.1124/pr.57.4.4 · Cited by 2,254
Crystal Structure of a Mammalian Voltage-Dependent Shaker Family K + Channel
Long, S. B., Campbell, E. B., & MacKinnon, R. (2005) · Science · doi:10.1126/science.1116269 · Cited by 2,124
Cited by
SLC6 Neurotransmitter Transporters: Structure, Function, and Regulation
Kristensen, A. S., Andersen, J., Jørgensen, T. N., Sørensen, L., Eriksen, J., Loland, C. J., Strømgaard, K., & Gether, U. (2011) · Pharmacological Reviews · doi:10.1124/pr.108.000869 · Cited by 864
French, J. A., Lawson, J. A., Yapici, Z., Ikeda, H., Polster, T., Nabbout, R., Curatolo, P., de Vries, P. J., Dlugos, D. J., Berkowitz, N., et al. (2016) · The Lancet · doi:10.1016/s0140-6736(16)31419-2 · Cited by 764
Adjunctive perampanel for refractory partial-onset seizures: Randomized phase III study 304
French, J. A., Krauss, G. L., Biton, V., Squillacote, D., Yang, H., Laurenza, A., Kumar, D., Rogawski, M. A., Campanille, V., Floridia, J., et al. (2012) · Neurology · doi:10.1212/wnl.0b013e3182635735 · Cited by 479
Self-citationRandomized phase III study 306: Adjunctive perampanel for refractory partial-onset seizures
Krauss, G. L., Serratosa, J. M., Villanueva, V., Endziniene, M., Hong, Z., French, J., Yang, H., Squillacote, D., Edwards, H. B., Zhu, J., et al. (2012) · Neurology · doi:10.1212/wnl.0b013e318254473a · Cited by 431
Adenosine receptors and brain diseases: neuroprotection and neurodegeneration
Gomes, C. V., Kaster, M. P., Tomé, A. R., Agostinho, P. M., & Cunha, R. A. (2011) · Biochimica et Biophysica Acta (BBA) - Biomembranes · doi:10.1016/j.bbamem.2010.12.001 · Cited by 419
Targeting LDH enzymes with a stiripentol analog to treat epilepsy
Sada, N., Lee, S., Katsu, T., Otsuki, T., & Inoue, T. (2015) · Science · doi:10.1126/science.aaa1299 · Cited by 413
Hanada, T., Hashizume, Y., Tokuhara, N., Takenaka, O., Kohmura, N., Ogasawara, A., Hatakeyama, S., Ohgoh, M., Ueno, M., & Nishizawa, Y. (2011) · Epilepsia · doi:10.1111/j.1528-1167.2011.03109.x · Cited by 411
Metabolic Control of Vesicular Glutamate Transport and Release
Juge, N., Gray, J. A., Omote, H., Miyaji, T., Inoue, T., Hara, C., Uneyama, H., Edwards, R. H., Nicoll, R. A., & Moriyama, Y. (2010) · Neuron · doi:10.1016/j.neuron.2010.09.002 · Cited by 400
GABA and Glutamate Transporters in Brain
Zhou, Y., & Danbolt, N. C. (2013) · Frontiers in Endocrinology · doi:10.3389/fendo.2013.00165 · Cited by 343
Mechanisms of Action of Antiseizure Drugs and the Ketogenic Diet
Rogawski, M. A., Löscher, W., & Rho, J. M. (2016) · Cold Spring Harbor Perspectives in Medicine · doi:10.1101/cshperspect.a022780 · Cited by 336
Self-citationGunthorpe, M. J., Large, C. H., & Sankar, R. (2012) · Epilepsia · doi:10.1111/j.1528-1167.2011.03365.x · Cited by 319
Antiepileptic drug therapy the story so far
Brodie, M. J. (2010) · Seizure · doi:10.1016/j.seizure.2010.10.027 · Cited by 298
Gillard, M., Fuks, B., Leclercq, K., & Matagne, A. (2011) · European Journal of Pharmacology · doi:10.1016/j.ejphar.2011.04.064 · Cited by 253
GABAA Receptors in Normal Development and Seizures: Friends or Foes?
Galanopoulou, A. (2008) · Current Neuropharmacology · doi:10.2174/157015908783769653 · Cited by 156
Yu, J., Proddutur, A., Elgammal, F. S., Ito, T., & Santhakumar, V. (2013) · Journal of Neurophysiology · doi:10.1152/jn.00891.2012 · Cited by 62
“The ability of tonic GABAergic inhibition to regulate excitability of projection neurons suggests that tonic IGABA may be modulated to prevent epileptogenesis (Meldrum and Rogawski 2007).”
BackgroundWu, P.-P., Cao, B.-R., Tian, F.-Y., & Gao, Z.-B. (2024) · Neuroscience Bulletin · doi:10.1007/s12264-023-01138-2 · Cited by 35
Kathwate, G. H., Shinde, R. B., & Karuppayil, S. M. (2015) · ASSAY and Drug Development Technologies · doi:10.1089/adt.2015.29007.ghkdrrr · Cited by 25
Metadata
- Authors
- Meldrum, B. S., & Rogawski, M. A.
- Venue
- Neurotherapeutics
- Publisher
- Elsevier BV
- Published
- 2007-01
- Volume
- 4
- Issue
- 1
- Pages
- 18-61
- ISSN
- 1878-7479 (ISSN-L)
- OpenAlex
- W2065214055
- Cited by
- 468
- References
- 393
- FWCI
- 17.83
- Type
- journal article
- Language
- en
- Open access
- bronze
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.